Calderón-Goercke, MónicaLoricera, JavierAldasoro, VicenteCastañeda, SantosVilla, IgnacioHumbría, AliciaMoriano, ClaraRomero-Yuste, SusanaNarváez, JavierGómez-Arango, CatalinaPérez-Pampín, EvaMelero, RafaelBecerra-Fernández, ElenaRevenga, MarcelinoÁlvarez-Rivas, NoeliaGalisteo, CarlesSivera, FranciscaOlivé-Marqués, AlejandroÁlvarez Del Buergo, MaríaMarena-Rojas, LuisaFernández-López, CarlosNavarro, FranciscoRaya, EnriqueGalindez-Agirregoikoa, EvaArca, BeatrizSolans-Laqué, RoserConesa, ArantxaHidalgo, CristinaVázquez, CarlosRomán-Ivorra, José AndrésLluch, PauManrique-Arija, SaraVela, PalomaDe Miguel, EugenioTorres-Martín, CarmenNieto, Juan CarlosOrdas-Calvo, CarmenSalgado-Pérez, EvaLuna-Gomez, CristinaToyos-Sáenz de Miera, F JavierFernández-Llanio, NagoreGarcía, AntonioLarena, CarmenPalmou-Fontana, NataliaCalvo-Río, VanesaPrieto-Peña, DianaGonzález-Vela, CarmenCorrales, AlfonsoVarela-García, MaríaAurrecoechea, ElenaDos Santos, RaquelGarcía-Manzanares, ÁngelOrtego, NorbertoFernández, SabelaOrtiz-Sanjuán, FranciscoCorteguera, MontserratHernández, José LGonzález-Gay, Miguel ÁBlanco, Ricardo2023-01-252023-01-252019-01-05http://hdl.handle.net/10668/13431Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in unselected patients with GCA in clinical practice Methods: Observational, open-label multicenter study from 40 national referral centers of GCA patients treated with TCZ due to inefficacy or adverse events of previous therapy. Outcomes variables were improvement of clinical features, acute phase reactants, glucocorticoid-sparing effect, prolonged remission and relapses. A comparative study was performed: (a) TCZ route (SC vs. IV); (b) GCA duration (≤6 vs. >6 months); (c) serious infections (with or without); (d) ≤15 vs. >15 mg/day at TCZ onset. 134 patients; mean age, 73.0 ± 8.8 years. TCZ was started after a median [IQR] time from GCA diagnosis of 13.5 [5.0-33.5] months. Ninety-eight (73.1%) patients had received immunosuppressive agents. After 1 month of TCZ 93.9% experienced clinical improvement. Reduction of CRP from 1.7 [0.4-3.2] to 0.11 [0.05-0.5] mg/dL (p  In clinical practice, TCZ yields a rapid and maintained improvement of refractory GCA. Serious infections appear to be higher than in clinical trials.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Biological therapyGiant cell arteritisLarge-vessel vasculitisTocilizumabAgedAged, 80 and overAntibodies, Monoclonal, HumanizedFemaleGiant Cell ArteritisHumansImmunosuppressive AgentsMaleMiddle AgedTreatment Outcomeresearch article30655091open access10.1016/j.semarthrit.2019.01.0031532-866Xhttps://repositorio.unican.es/xmlui/bitstream/10902/16652/3/TocilizumabGiantCell_nv_articulo_6347.pdf